These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND CDX2, CDX3, 1045, ENSG00000165556, Q99626 AND Prognosis
109 results:

  • 1. [Clinicopathological analysis of gastric adenocarcinoma with elevated serum alpha-fetoprotein and enteroblastic differentiation].
    Zan LK; Shen LL; Zhang X; Gao N; Tian BG; Geng XX; Peng X; Li JW; Bu P; Zhao GH
    Zhonghua Zhong Liu Za Zhi; 2024 Jul; 46(7):686-695. PubMed ID: 39034804
    [No Abstract]    [Full Text] [Related]  

  • 2. Microenvironment, systemic inflammatory response and tumor markers considering consensus molecular subtypes of colorectal cancer.
    Jakab A; Patai ÁV; Darvas M; Tormássi-Bély K; Micsik T
    Pathol Oncol Res; 2024; 30():1611574. PubMed ID: 38645565
    [No Abstract]    [Full Text] [Related]  

  • 3. Concomitant expression patterns of cdx2 and SATB2 as prognostic factors in stage III colorectal cancers.
    Lee JA; Park HE; Jin HY; Jin L; Cho NY; Bae JM; Kim JH; Kang GH
    Ann Diagn Pathol; 2024 Aug; 71():152289. PubMed ID: 38555678
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. POLE-Mutant Colon Adenocarcinoma-Case Presentation and Histopathological Evaluation.
    Pancsa T; Vasas B; Melegh Z; Tóth E; Torday L; Sejben A
    J Gastrointest Cancer; 2024 Jun; 55(2):961-964. PubMed ID: 38175383
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. ZEB1 hypermethylation is associated with better prognosis in patients with colon cancer.
    Fernandez-De-Los-Reyes I; Gomez-Dorronsoro M; Monreal-Santesteban I; Fernandez-Fernandez A; Fraga M; Azcue P; Alonso L; Fernandez-Marlasca B; Suarez J; Cordoba-Iturriagagoitia A; Guerrero-Setas D
    Clin Epigenetics; 2023 Dec; 15(1):193. PubMed ID: 38093305
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Multivariate Prognostic Models for Patients with Stages I and Ii Colon Carcinoma: a Strobe-Compliant Retrospective Cohort Study.
    Oñate-Ocaña LF; Herrera-Goepfert R; Avilés-Salas A; Cortés CC; González-Trejo S; Carrillo JF; Ruiz-García E; Ochoa-Carrillo FJ; Aiello-Crocifoglio V; García-Cuellar CM
    Rev Invest Clin; 2023; 75(5):259-271. PubMed ID: 37918013
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. The prognostic potential of cdx2 in colorectal cancer: Harmonizing biology and clinical practice.
    Badia-Ramentol J; Gimeno-Valiente F; Duréndez E; Martínez-Ciarpaglini C; Linares J; Iglesias M; Cervantes A; Calon A; Tarazona N
    Cancer Treat Rev; 2023 Dec; 121():102643. PubMed ID: 37871463
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Loss of SATB2 and cdx2 expression is associated with DNA mismatch repair protein deficiency and BRAF mutation in colorectal cancer.
    Li J; Zeng Q; Lin J; Huang H; Chen L
    Med Mol Morphol; 2024 Mar; 57(1):1-10. PubMed ID: 37583001
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. cdx2 Is a Prognostic Biomarker for Unresectable Metastatic colorectal cancer.
    Mukohyama J; Agawa K; Yamashita K; Matsuda T; Shinoda M; Itano O; Kakeji Y
    Anticancer Res; 2023 Aug; 43(8):3763-3767. PubMed ID: 37500172
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Deciphering Brain Metastasis Stem Cell Properties From colorectal cancer Highlights Specific Stemness Signature and Shared Molecular Features.
    Desette A; Guichet PO; Emambux S; Masliantsev K; Cortes U; Ndiaye B; Milin S; George S; Faigner M; Tisserand J; Gaillard A; Brot S; Wager M; Tougeron D; Karayan-Tapon L
    Cell Mol Gastroenterol Hepatol; 2023; 16(5):757-782. PubMed ID: 37482243
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Pattern of expression of cdx2 in colorectal cancer and its role in prognosis.
    Singh J; Rajesh NG; Dubashi B; Maroju NK; Ganesan P; Matta KK; Charles I; Kayal S
    J Cancer Res Ther; 2022 Dec; 18(Supplement):S420-S427. PubMed ID: 36510997
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Immunohistochemical analysis of the distribution of RANKL: a case of disseminated carcinomatosis of bone marrow as the first presentation of relapse in curatively resected colorectal cancer.
    Shimada Y; Nagaba Y; Okawa H; Ehara K; Okada S; Naito M; Yokomori H
    Med Mol Morphol; 2023 Jun; 56(2):138-143. PubMed ID: 36478259
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. cdx2 as a Predictive Biomarker Involved in Immunotherapy Response Suppresses Metastasis through EMT in colorectal cancer.
    Wang YS; Kou Y; Zhu RT; Han BW; Li CH; Wang HJ; Wu HB; Xia TM; Che XM
    Dis Markers; 2022; 2022():9025668. PubMed ID: 36277982
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer.
    Mochizuki K; Kudo SE; Kato K; Kudo K; Ogawa Y; Kouyama Y; Takashina Y; Ichimasa K; Tobo T; Toshima T; Hisamatsu Y; Yonemura Y; Masuda T; Miyachi H; Ishida F; Nemoto T; Mimori K
    PLoS One; 2022; 17(10):e0273566. PubMed ID: 36264865
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Combination of cdx2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer.
    Derangère V; Lecuelle J; Lepage C; Aoulad-Ben Salem O; Allatessem BM; Ilie A; Bouché O; Phelip JM; Baconnier M; Pezet D; Sebbagh V; Terrebonne E; Bouard G; Jooste V; Bouvier AM; Molimard C; Monnien F; Gonzalez D; Le Malicot K; Rageot D; Truntzer C; Bibeau F; Ghiringhelli F;
    Eur J Cancer; 2022 Sep; 172():221-230. PubMed ID: 35785606
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. The Complete Loss of p53 Expression Uniquely Predicts Worse prognosis in colorectal cancer.
    Nagao K; Koshino A; Sugimura-Nagata A; Nagano A; Komura M; Ueki A; Ebi M; Ogasawara N; Tsuzuki T; Kasai K; Takahashi S; Kasugai K; Inaguma S
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328677
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Current Perspectives on the Importance of Pathological Features in Prognostication and Guidance of Adjuvant Chemotherapy in Colon cancer.
    Chen K; Wang H; Collins G; Hollands E; Law IYJ; Toh JWT
    Curr Oncol; 2022 Feb; 29(3):1370-1389. PubMed ID: 35323316
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. cdx2 controls genes involved in the metabolism of 5-fluorouracil and is associated with reduced efficacy of chemotherapy in colorectal cancer.
    Delhorme JB; Bersuder E; Terciolo C; Vlami O; Chenard MP; Martin E; Rohr S; Brigand C; Duluc I; Freund JN; Gross I
    Biomed Pharmacother; 2022 Mar; 147():112630. PubMed ID: 35051860
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. [A Case of Multiple Hepatic Metastases after Surgery for Low Differentiated Mucous cancer of Sigmoid Colon with Notable Mesenteric Infiltration in Which Chemotherapy Was Effective].
    Tani H; Takaishi H; Ihara T; Murakami D; Aratake K
    Gan To Kagaku Ryoho; 2021 Dec; 48(13):2155-2157. PubMed ID: 35045523
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Pathological Features and Prognostication in colorectal cancer.
    Chen K; Collins G; Wang H; Toh JWT
    Curr Oncol; 2021 Dec; 28(6):5356-5383. PubMed ID: 34940086
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 6.